Novo Nordisk is a leading global pharmaceutical company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change, based on our experience and heritage in diabetes, to defeat serious chronic diseases such as obesity, haemophilia, growth disorders and other diseases. We do this through innovative scientific discoveries, by expanding access to our medicines and by working on the prevention and eventual cure of diseases. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in about 170 countries. Novo Nordisk shares are listed on the Nasdaq in Copenhagen (Novo-B) and the New York Stock Exchange (NVO). For more information, visit novonordisk.com and company profiles on Facebook, X, LinkedIn and YouTube platforms.